
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Dermatologists will inevitably increase compliance among ethnic patients when treating scalp conditions such as seborrheic dermatitis or atopic dermatitis if they inquire about the types of hair products the patient normally uses.






